In patients with long atherosclerotic femoropopliteal lesions, the Eluvia paclitaxel-eluting stent is expected to be a popular option for endovascular operators (physicians) in the U.S. Data on how patients with long lesions fared is of considerable value. Coming on the heels of the recent FDA approval of the stent, the data give a glimpse of how the new device will fare in real-world patients. Hear from William A. Gray, MD, Chief of Cardiovascular Diseases at Lankenau Heart Institute, part of Main Line Health speaking at the VIVA 2018 meeting in Las Vegas, NV.
Click here for the full press release on the Imperial Trial.